2026 Q1 -tulosraportti
Vain PDF
33 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 11 091 | - | - | ||
| 2 523 | - | - | ||
| 21 455 | - | - | ||
| 2 948 | - | - | ||
| 469 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·13 t sittenstock status Canngo: Sold out at a pharmacy Now it's the third time Weeco Astrum 10-10 is sold out at this pharmacy, within a very short time ?? At this pharmacy, 1 ml. costs 4.52 €, most pharmacies charge 4.45 € per ml. We know that when a pharmacy raises the price of medicine, it's because it's popular and many people buy it. When it's sold out here, we must expect that it's because many doctors are prescribing in this area. The pharmacy is located in Düsseldorf. Stenocare's earnings will not be affected by it being sold out at this pharmacy, because users redeem their prescription at another pharmacy. the rest Status Quo.- ·15 t sittenI just found out that the politicians in Germany will have stopped subsidies for flower medicine. Weeco Astrum10-10 is considered general medicine in Germany. Therefore, the oil will not be affected when it is adopted. https://www.apotheke-adhoc.de/rubriken/detail/medizinisches-cannabis/cannabis-keine-blueten-fuer-versicherte/#
·1 päivä sitten·1 päivä sittenSame industry, so I thought it could be interesting here.·1 päivä sittenAlways interesting to hear how other companies in the same industry are doing, as that way one can get an impression of how the market is doing, so to speak, so please keep it up. 3D only thinks what he writes is interesting, and that even though it's 100 pure hype.- ·5.6.Stock status Canngo: Weeco Astrum is back in stock. They have now been sold out 2 times within a short period, so we must expect them to ensure they order more in stock so it doesn't happen again. This is a completely unique situation. We are looking directly into the engine room. This is only possible because the German cash registers are not connected to the inventory. Many pieces of information have emerged since I started with stock status. Therefore, I will write what we know in bullet points to maintain an overview. We know that: * Weeco astrum10-10 has the 4 advantages for doctors to start prescribing. Approval from the 2 major Insurance companies 100% refund Fast track status Resembles general medicine * Weeco is running a campaign for Astrum10-10. For this reason, Weeco will allocate resources to spread the oil, and when there is a campaign, there will be some sub-goals for the salespeople, who will receive a bonus when they reach their targets. For this reason, the salespeople will have a strong interest in getting doctors to prescribe the oil. * I started on May 13, selecting 21 platforms out of 250, which is approx. 8%. * Stenocare records when prescriptions are redeemed. * It is only if customers continuously redeem prescriptions for the oil that it will be stocked; otherwise, it will be an order item. * There have been 4 days with status Quo, out of 19 weekdays, * If telemedicine is changed, Weeco astrum 10-10 will be held harmless. * The Supreme Court's ruling has no impact on the oil. * Users praise the oil, via Google and other platforms. We don't need to wait for management to tell us how they think things are going; we can decide that ourselves. We can see in real-time how the rollout of Weeco Astrum10-10 in Germany is progressing.·3 päivää sittencrankyrabbit Weeco has pulled out all the stops to get Weeco astrum10-10 rolled out in Germany. We can confirm, in real-time, that so far, Weeco has succeeded in getting more and more doctors to issue prescriptions, and it is ONLY because of the four advantages that doctors are willing to prescribe the oil. The difference between now and 2022, when Stenocare started to launch oil in Germany and it did not succeed, is because, in 2022, the oil did NOT have these four advantages, which it gained in 2025. You should also remember that ADREX has been active throughout 2025, instructing doctors on how to write applications to insurance companies. Weeco builds upon this work that ADREX has performed. When the stock rises, I will make money; if the stock maintains its current level, I will buy more when I have cash. In my case, I will make money regardless of whether the stock rises or not, so it is not to hype the stock that I am writing the above and about inventory status; it is just information that I am sharing here with you, and then you can use it for whatever suits you best. https://weeco.com/2026/02/10/weeco-pharma-gmbh-startet-strategische-partnerschaft-mit-stenocare-zur-einfuehrung-des-neuen-astrum-oelprodukts-in-deutschland/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
33 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·13 t sittenstock status Canngo: Sold out at a pharmacy Now it's the third time Weeco Astrum 10-10 is sold out at this pharmacy, within a very short time ?? At this pharmacy, 1 ml. costs 4.52 €, most pharmacies charge 4.45 € per ml. We know that when a pharmacy raises the price of medicine, it's because it's popular and many people buy it. When it's sold out here, we must expect that it's because many doctors are prescribing in this area. The pharmacy is located in Düsseldorf. Stenocare's earnings will not be affected by it being sold out at this pharmacy, because users redeem their prescription at another pharmacy. the rest Status Quo.
- ·15 t sittenI just found out that the politicians in Germany will have stopped subsidies for flower medicine. Weeco Astrum10-10 is considered general medicine in Germany. Therefore, the oil will not be affected when it is adopted. https://www.apotheke-adhoc.de/rubriken/detail/medizinisches-cannabis/cannabis-keine-blueten-fuer-versicherte/#
- ·1 päivä sitten·1 päivä sittenSame industry, so I thought it could be interesting here.·1 päivä sittenAlways interesting to hear how other companies in the same industry are doing, as that way one can get an impression of how the market is doing, so to speak, so please keep it up. 3D only thinks what he writes is interesting, and that even though it's 100 pure hype.
- ·5.6.Stock status Canngo: Weeco Astrum is back in stock. They have now been sold out 2 times within a short period, so we must expect them to ensure they order more in stock so it doesn't happen again. This is a completely unique situation. We are looking directly into the engine room. This is only possible because the German cash registers are not connected to the inventory. Many pieces of information have emerged since I started with stock status. Therefore, I will write what we know in bullet points to maintain an overview. We know that: * Weeco astrum10-10 has the 4 advantages for doctors to start prescribing. Approval from the 2 major Insurance companies 100% refund Fast track status Resembles general medicine * Weeco is running a campaign for Astrum10-10. For this reason, Weeco will allocate resources to spread the oil, and when there is a campaign, there will be some sub-goals for the salespeople, who will receive a bonus when they reach their targets. For this reason, the salespeople will have a strong interest in getting doctors to prescribe the oil. * I started on May 13, selecting 21 platforms out of 250, which is approx. 8%. * Stenocare records when prescriptions are redeemed. * It is only if customers continuously redeem prescriptions for the oil that it will be stocked; otherwise, it will be an order item. * There have been 4 days with status Quo, out of 19 weekdays, * If telemedicine is changed, Weeco astrum 10-10 will be held harmless. * The Supreme Court's ruling has no impact on the oil. * Users praise the oil, via Google and other platforms. We don't need to wait for management to tell us how they think things are going; we can decide that ourselves. We can see in real-time how the rollout of Weeco Astrum10-10 in Germany is progressing.·3 päivää sittencrankyrabbit Weeco has pulled out all the stops to get Weeco astrum10-10 rolled out in Germany. We can confirm, in real-time, that so far, Weeco has succeeded in getting more and more doctors to issue prescriptions, and it is ONLY because of the four advantages that doctors are willing to prescribe the oil. The difference between now and 2022, when Stenocare started to launch oil in Germany and it did not succeed, is because, in 2022, the oil did NOT have these four advantages, which it gained in 2025. You should also remember that ADREX has been active throughout 2025, instructing doctors on how to write applications to insurance companies. Weeco builds upon this work that ADREX has performed. When the stock rises, I will make money; if the stock maintains its current level, I will buy more when I have cash. In my case, I will make money regardless of whether the stock rises or not, so it is not to hype the stock that I am writing the above and about inventory status; it is just information that I am sharing here with you, and then you can use it for whatever suits you best. https://weeco.com/2026/02/10/weeco-pharma-gmbh-startet-strategische-partnerschaft-mit-stenocare-zur-einfuehrung-des-neuen-astrum-oelprodukts-in-deutschland/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 11 091 | - | - | ||
| 2 523 | - | - | ||
| 21 455 | - | - | ||
| 2 948 | - | - | ||
| 469 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
33 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·13 t sittenstock status Canngo: Sold out at a pharmacy Now it's the third time Weeco Astrum 10-10 is sold out at this pharmacy, within a very short time ?? At this pharmacy, 1 ml. costs 4.52 €, most pharmacies charge 4.45 € per ml. We know that when a pharmacy raises the price of medicine, it's because it's popular and many people buy it. When it's sold out here, we must expect that it's because many doctors are prescribing in this area. The pharmacy is located in Düsseldorf. Stenocare's earnings will not be affected by it being sold out at this pharmacy, because users redeem their prescription at another pharmacy. the rest Status Quo.
- ·15 t sittenI just found out that the politicians in Germany will have stopped subsidies for flower medicine. Weeco Astrum10-10 is considered general medicine in Germany. Therefore, the oil will not be affected when it is adopted. https://www.apotheke-adhoc.de/rubriken/detail/medizinisches-cannabis/cannabis-keine-blueten-fuer-versicherte/#
- ·1 päivä sitten·1 päivä sittenSame industry, so I thought it could be interesting here.·1 päivä sittenAlways interesting to hear how other companies in the same industry are doing, as that way one can get an impression of how the market is doing, so to speak, so please keep it up. 3D only thinks what he writes is interesting, and that even though it's 100 pure hype.
- ·5.6.Stock status Canngo: Weeco Astrum is back in stock. They have now been sold out 2 times within a short period, so we must expect them to ensure they order more in stock so it doesn't happen again. This is a completely unique situation. We are looking directly into the engine room. This is only possible because the German cash registers are not connected to the inventory. Many pieces of information have emerged since I started with stock status. Therefore, I will write what we know in bullet points to maintain an overview. We know that: * Weeco astrum10-10 has the 4 advantages for doctors to start prescribing. Approval from the 2 major Insurance companies 100% refund Fast track status Resembles general medicine * Weeco is running a campaign for Astrum10-10. For this reason, Weeco will allocate resources to spread the oil, and when there is a campaign, there will be some sub-goals for the salespeople, who will receive a bonus when they reach their targets. For this reason, the salespeople will have a strong interest in getting doctors to prescribe the oil. * I started on May 13, selecting 21 platforms out of 250, which is approx. 8%. * Stenocare records when prescriptions are redeemed. * It is only if customers continuously redeem prescriptions for the oil that it will be stocked; otherwise, it will be an order item. * There have been 4 days with status Quo, out of 19 weekdays, * If telemedicine is changed, Weeco astrum 10-10 will be held harmless. * The Supreme Court's ruling has no impact on the oil. * Users praise the oil, via Google and other platforms. We don't need to wait for management to tell us how they think things are going; we can decide that ourselves. We can see in real-time how the rollout of Weeco Astrum10-10 in Germany is progressing.·3 päivää sittencrankyrabbit Weeco has pulled out all the stops to get Weeco astrum10-10 rolled out in Germany. We can confirm, in real-time, that so far, Weeco has succeeded in getting more and more doctors to issue prescriptions, and it is ONLY because of the four advantages that doctors are willing to prescribe the oil. The difference between now and 2022, when Stenocare started to launch oil in Germany and it did not succeed, is because, in 2022, the oil did NOT have these four advantages, which it gained in 2025. You should also remember that ADREX has been active throughout 2025, instructing doctors on how to write applications to insurance companies. Weeco builds upon this work that ADREX has performed. When the stock rises, I will make money; if the stock maintains its current level, I will buy more when I have cash. In my case, I will make money regardless of whether the stock rises or not, so it is not to hype the stock that I am writing the above and about inventory status; it is just information that I am sharing here with you, and then you can use it for whatever suits you best. https://weeco.com/2026/02/10/weeco-pharma-gmbh-startet-strategische-partnerschaft-mit-stenocare-zur-einfuehrung-des-neuen-astrum-oelprodukts-in-deutschland/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 11 091 | - | - | ||
| 2 523 | - | - | ||
| 21 455 | - | - | ||
| 2 948 | - | - | ||
| 469 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt